Trial Profile
The effect of methylphenidate, atomoxetine and citalopram versus placebo on behavioural and physiological indices of executive control in healthy individuals.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 16 Jul 2019
Price :
$35
*
At a glance
- Drugs Atomoxetine (Primary) ; Citalopram (Primary) ; Methylphenidate (Primary)
- Indications Anxiety disorders; Attention-deficit hyperactivity disorder; Depressive disorders; Huntington's disease; Social phobia; Somatoform disorders
- Focus Pharmacodynamics
- 28 Jun 2012 Status changed from recruiting to completed as reported by Australian New Zealand Clinical Trials Registry record.
- 04 Aug 2009 New trial record